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Oncostatin M promotes excitotoxicity by
inhibiting glutamate uptake in astrocytes:
implications in HIV-associated neurotoxicity
Shamsudheen Moidunny1, Marco Matos2, Evelyn Wesseling3, Santanu Banerjee1, David J. Volsky4,
Rodrigo A. Cunha2, Paula Agostinho2, Hendrikus W. Boddeke3 and Sabita Roy1,5*
Abstract
Background: Elevated levels of oncostatin M (OSM), an interleukin-6 cytokine family member, have been observed
in HIV-1-associated neurocognitive disorders (HAND) and Alzheimer’s disease. However, the function of OSM in these
disease conditions is unclear. Since deficient glutamate uptake by astrocytes is instrumental in HAND-associated
neurotoxicity, we hypothesized that OSM impairs glutamate uptake in astrocytes and thereby promotes neuronal
excitotoxicity.
Methods: Primary cultures of mouse cortical astrocytes, neurons, microglia, and BV2 cell line were used. The expression
of glutamate transporters (GLAST/EAAT1 and GLT-1/EAAT2) was investigated using real-time PCR and Western blot, and
their activity was assessed by measuring 3H-D-aspartate uptake. Neuronal toxicity was measured using the colorimetric
MTT (3-(4,5-dimethylthiazol-2-yl-) 2,5-diphenyltetrazolium bromide) assay and immunocytochemistry. A chimeric HIV-1
that infects murine cells (EcoHIV/NL4-3-GFP virus (EcoHIV)) was used to investigate whether the virus induces OSM, OSM
receptor (OSMR)-β, glycoprotein 130 (gp130), GLT-1, GLAST (mRNA and protein), and OSM release (ELISA) in cultured BV2
cells, primary microglia, or astrocytes. Statistical analyses of the data were performed using one-way ANOVA (to allow
multiple comparisons) and two-tailed Student’s t test.
Results: OSM treatment (10 ng/mL) time-dependently reduced GLAST and GLT-1 expression and inhibited
3H-D-aspartate uptake in cultured astrocytes in a concentration-dependent manner, an effect prevented by the Janus
kinase (JAK)/signal transducers and activators of transcription (STAT)3 inhibitor AG490. Down-regulation of astrocytic
glutamate transport by OSM resulted in NMDA receptor-dependent excitotoxicity in cortical neurons. Infection with
EcoHIV induced OSM gene expression and protein release in BV2 cells and microglia, but not in astrocytes. Conversely,
EcoHIV caused a fivefold increase in OSMR-β mRNA (but not gp130) and protein in astrocytes, but not in microglia, which
did not express OSMR-β protein. Finally, astrocytic expression of GLAST gene was unaffected by EcoHIV, whereas GLT-1
mRNA was increased by twofold.
Conclusions: We provide first evidence that activation of JAK/STAT3 signaling by OSM inhibits glutamate uptake in
astrocytes, which results in neuronal excitotoxicity. Our findings with EcoHIV suggest that targeting OSMR-β signaling
in astrocytes might alleviate HIV-1-associated excitotoxicity.
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Background
Astrocytes are the most abundant cell type of the brain [1],
where one of their major functions is to support neurons.
They ensure optimal conditions by maintaining local ion
and pH homeostasis, regulating neurotransmitters, and
clearing metabolic waste [2]. In addition, they store glyco-
gen and supply nutrients to neurons [3]. Dysfunction of
astrocytes could therefore have serious consequences for
neuron survival. One major cause of neuronal death in the
central nervous system (CNS) is excessive release of glu-
tamate and subsequent activation of neuronal N-methyl D-
aspartate (NMDA) receptors [4, 5]. Astrocytes prevent this
neuronal excitotoxicity by sequestration of extracellular glu-
tamate, which is mediated mainly by two Na+-dependent
transporters: glutamate aspartate transporter (GLAST/
EAAT1) and glutamate transporter-1 (GLT-1/EAAT2) [6,
7]. Consistently, loss of astrocytic glutamate uptake and
metabolism is one of the key factors responsible for neuro-
toxicity associated with amyotrophic lateral sclerosis (ALS)
[8, 9], Alzheimer’s disease (AD) [10], and HIV-associated
neurocognitive disorders (HAND) [11, 12]. In order to de-
velop therapeutic interventions against excitotoxicity asso-
ciated with these CNS disorders, it is critical to identify
factors that regulate astrocytic glutamate transporter ex-
pression and activity.
Inflammation of the CNS generally causes a reduction
of glutamate transporter expression and consequently
dampens glutamate uptake capacity of astrocytes [13, 14].
Thus, pro-inflammatory mediators such as tumor necrosis
factor (TNF)-α and interleukin (IL)-1β differentially regu-
late glutamate transporter expression and glutamate
uptake capacity in astrocytes [13–16]; however, the mo-
lecular mechanisms that link inflammatory processes and
decreased astrocytic glutamate uptake are not well under-
stood. Recent evidence suggest that oncostatin M (OSM),
a pleiotropic cytokine belonging to the IL-6 family, might
influence neurodegenerative processes associated with a
variety of brain diseases. OSM levels have been found to
be elevated in both serum and brain lesions of multiple
sclerosis (MS) patients [17, 18]. In addition, high levels of
OSM are spontaneously secreted by peripheral blood
mononuclear cells (PBMCs) isolated from MS, AD, and
HAND patients [17, 19, 20]. Although, the precise func-
tion of OSM in these disease conditions is unclear, there is
limited evidence suggesting that OSM disrupts blood-
brain barrier function [21, 22] and mediates pro- and anti-
inflammatory effects in the CNS [23–25]. In addition, we
have previously shown, along with others, that activation
of neuronal OSM receptors protects them against glutam-
ate- and NMDA-induced excitotoxicity [26, 27], poten-
tially by stimulating expression of the neuromodulatory
adenosine A1 receptors [26]. Furthermore, a recent study
showed that overexpression of OSM receptor (OSMR)-β
in neurons is protective against ischemic stroke, whereas
decreased neuronal OSMR-β expression results in worse
stroke outcomes [28]. In contrast, earlier studies demon-
strated that OSM actually mediates HIV-associated neuro-
toxicity in vitro [29]; however, the potential mechanism(s)
are not yet understood.
Like neurons, astrocytes may also serve as an import-
ant target for OSM in the CNS as its receptor subunits
(OSMR-β and glycoprotein 130 (gp130)) are abundantly
expressed in these cells [30, 31]. Activation of OSM re-
ceptors in astrocytes has been shown to induce reactive
astrogliosis [32, 33] and stimulate expression of different
matrix metalloproteinases [34] and pro-inflammatory
factors including IL-6 [35], prostaglandin (PG) E2, and
cyclooxygenase-2 [30]. In addition, OSM has been shown
to induce expression of α1-antichymotrypsin (ACT) in as-
trocytes [36]. ACT is an acute phase protein that has been
associated with the formation of amyloid-β deposits found
in brain tissue of AD patients [37, 38]. Taken together, these
findings suggest that OSM might directly regulate the in-
flammatory activity of astrocytes in the CNS.
Despite the clear role of OSM in neurocognitive disease,
the involvement of OSM in the regulation of glutamate
uptake in astrocytes has not yet been addressed. We hy-
pothesized that OSM down-regulates glutamate uptake
process in astrocytes and thereby promote neuronal excito-
toxicity. Since OSM may play an important role in HIV-1-
associated neuropathogenesis [20, 29], we further investi-
gated whether infection with a chimeric HIV-1 (EcoHIV/
NL4-3-GFP virus (EcoHIV)) [39, 40] induces the expres-
sion of OSM and/or its receptors (OSMR-β and gp130) in
cultured microglia and astrocytes.
Methods
Chemicals and reagents
3H-D-aspartate (specific activity = 10–25 Ci/mmol) was
obtained from PerkinElmer (MA, USA) and Aquasafe 500
Plus liquid scintillation cocktail from Zinsser Analytic
(Frankfurt, Germany). Neurobasal media, Hank’s buffered
salt solution (HBSS), phosphate-buffered saline (PBS), so-
dium pyruvate, L-glutamine, penicillin-streptomycin, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
glutaMAX-1, and B27 supplement were from Gibco
(Breda, The Netherlands). Dulbecco’s modified Eagle
medium (DMEM) media and fetal calf serum (FCS) were
from PAA Laboratories (Cölbe, Germany). Trypsin was
obtained from Life Technologies (Breda, The Netherlands).
All other cell medium components, recombinant mouse
OSM, recombinant mouse IL-6, D-aspartate, L-leucine
methyl ester (LME), N-methyl-D-glucamine (NMG), and
the dyes used to stain cell nuclei (Hoechst 33342 and pro-
pidium iodide) were purchased from Sigma-Aldrich
(Zwijndrecht, The Netherlands). DL-threo-β-benzyloxyas-
partic acid (TBOA) and MEK1/2 inhibitor U0126 were ob-
tained from Tocris Bioscience (Bristol, UK). Janus kinase
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(JAK) inhibitor (AG490) and phosphatidylinositol 3-kinase
(PI3K) inhibitor (LY294002) were obtained from Calbio-
chem (CA, USA). Reagents used in immunoblotting exper-
iments were purchased from Bio-Rad Laboratories, except
polyvinylidene fluoride (PVDF) membranes that were
obtained from Millipore (Amsterdam, The Netherlands).
Primary antibodies, mouse monoclonal anti-β-actin, rabbit
polyclonal anti-GLT-1/EAAT2, rabbit polyclonal anti-
GLAST/EAAT1 (C-terminus), and FITC-conjugated anti-
GFP were obtained from Abcam (Cambridge, UK); mouse
monoclonal anti-glial fibrillary acidic protein (GFAP) was
obtained from Millipore; goat polyclonal anti-OSMR-β
(AF662) was from R&D Systems (Minneapolis, USA);
mouse monoclonal anti-MAP2 and mouse monoclonal
anti-α-tubulin were obtained from Sigma-Aldrich; and pri-
mary antibodies against total and phosphorylated signal
transducers and activators of transcription (STAT)3, extra-
cellular signal-regulated kinase ½ (ERK1/2), and Akt were
obtained from Cell Signaling Technology (Bioke, Leiden,
The Netherlands). The fluorescent dye-conjugated second-
ary antibodies used for Western blot, donkey anti-mouse
IR Dye 680, and donkey anti-rabbit IR Dye 800CW were
obtained from LI-COR Biosciences (Cambridge, UK). The
fluorescent dye-conjugated secondary antibodies used for
immunocytochemistry: goat anti-rabbit CY3 was obtained
from Jackson ImmunoResearch Laboratories (Uden, The
Netherlands); and donkey anti-mouse Alexa Fluor 488 was
obtained from Molecular Probes (Breda, The Netherlands).
Animals
All procedures carried out were in strict accordance with
recommendations in the Guide for Care and Use of
Laboratory Animals of the National Institutes of Health,
and the regulations of the Ethical Committee for the use
of experimental animals of the University of Groningen,
The Netherlands (License number DEC 4623A and DEC
5913A), Institutional Animal Care and Use Committee of
the University of Minnesota (Protocol no: 1203A11091
and 1404A31457), as well as with the Portuguese law on
Animal Care and European Union guidelines (Directive
2010/63/EU). Wild-type C57BL/6J (1–2 days postnatal)
mice were obtained from Charles River and Central la-
boratory animal facility of Groningen. Wild-type C57BL/
6J (14–15 days embryonic) mice were obtained from
Harlan (Horst, The Netherlands). Animals were housed in
standard makrolon cages and maintained on a 12-h light/
dark cycle. They received food and water ad libitum.
Primary astrocyte culture
Primary astrocyte cultures were established from cerebral
cortices of postnatal (1–2 days) C57BL/6J mice according
to a previously described procedure [41], modified to re-
duce microglial contamination [42]. Approximately 2 weeks
after plating, microglial cells were mechanically separated
from the astrocytic monolayer by shake-off at 150 rpm for
1 h. This procedure was repeated twice with an interval of
4 days in vitro between each shake-off, followed by an over-
night shake-off at 240 rpm to remove oligodendrocyte
precursor cells. Enriched astrocytes were washed with
HBSS buffer (in mM: 137 NaCl, 5.3 KCl, 0.3 Na2HPO4, 0.4
KH2PO4, 4.2 NaHCO3, 5.6 D-glucose, pH 7.4) containing
1 mM ethylenediaminetetraacetic acid (EDTA) and further
detached using 0.1 % trypsin (diluted in HBSS). Cells were
reseeded with fresh astrocyte culture medium (DMEM
supplemented with 5 % FCS, 2 mM L-glutamine, 1 mM
sodium pyruvate, and 50 U/mL penicillin-streptomycin) in
multiwell plates (5 × 104 cells/cm2) and maintained in cul-
ture to confluence. To further reduce microglial contamin-
ation, confluent astrocyte cultures were treated with 5 mM
LME, a lysosomotropic agent [43], for 4–5 h. Astrocytes
were ready for experiments after 1–2 days. Our cell prepa-
rations had a high percentage of astrocytes (≥95 %), which
was confirmed by immunostaining against GFAP (astrocyte
marker) and CD11b (microglial marker) (Additional file 1:
Figure S1) [44]. Although with low abundance, it is possible
that the presence of microglial cells (approx. 5 %) in astro-
cyte cultures may influence some of the observations in this
study. Therefore, additional experiments were carried out
to verify astrocyte specificity of OSM effects in astrocyte
cultures treated with liposomal clodronate (1 mg/mL for
4 h; Encapsula NanoSciences LLC, TN, USA), which re-
sulted in complete depletion of microglial cells (Additional
file 2: Figure S2A).
BV2 cell line and primary microglia culture
The murine microglial BV2 cells were maintained in
DMEM media containing 10 % FCS at 37 °C in a 5 % CO2
incubator. Primary microglia cultures were established fol-
lowing their shake-off (150 rpm for 1 h) from mixed glial
culture flasks. The cells were cultured in standard DMEM
media (supplemented with 5 % FCS, 2 mM L-glutam-
ine, 1 mM sodium pyruvate and 50 U/mL penicillin-
streptomycin), diluted in 1:1 ratio with glial-
conditioned media.
Primary neuronal culture
Primary cultures of cortical neurons from mouse embryo
(~E15) were done as described previously [26]. Briefly, corti-
ces from embryonic brains were dissected in ice-cold HBSS
supplemented with 30 % glucose. Meninges were removed,
and the tissues were treated with trypsin before they were
gently dissociated by trituration in neuronal culture media
(neurobasal medium supplemented with 2 % B27, 1 mM
sodium pyruvate, 2 mM L-glutamine and 50 U/mL
penicillin-streptomycin). Cell suspension was filtered using
a cell strainer (70 μm; Falcon, Franklin Lakes, NJ, USA) be-
fore centrifugation (800 rpm for 10 min). Cells were then
seeded on poly-D-lysine (10 μg/mL)-coated 96-well plates
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(1 × 105 cells/well) and maintained in neuronal culture
media in a humidified atmosphere with 5 % CO2 at 37 °C.
Culture media was refreshed 24 h later to minimize culture
debris. The neuronal purity as determined by MAP2 stain-
ing was around 98 % [26]. Cultures were used after 5 days
in vitro.
EcoHIV infection
In the present work, we used EcoHIV/NL4-3-EGFP (re-
ferred to as EcoHIV, for brevity), a chimeric HIV-1 ex-
pressing enhanced green fluorescent protein (EGFP) as
an indicator, which was constructed on the backbone of
HIV-1/NL4-3, as described previously [39]. Infectious
EcoHIV stocks were propagated in HEK293TN cells as
described [40] and titered for the p24 HIV-1 core anti-
gen by ELISA, following the manufacturer’s instructions
(ZeptoMetrix Corporation, NY, USA). Cultured astro-
cytes, microglia, and BV2 cells were incubated with
35,000 pg of p24 (per 1 × 106 cells) during the incubation
time stated in the text. Viral infectivity of cells was
assessed by HIV LTR (long-term repeat) gene expression
and/or anti-GFP immunocytochemistry.
RNA isolation and reverse transcription polymerase chain
reaction (RT-PCR)
Cultured cells were lysed in guanidinium isothiocyanate/
mono-thioglycerol (GTC+) buffer and total RNA was ex-
tracted using a phenol-chloroform/iso-amyl alcohol step,
followed by DNAse 1 treatment. Purified messenger
ribonucleic acid (mRNA) was then transcribed into com-
plementary DNA (cDNA) as described previously [45].
The quality of the cDNA was examined using primers
for the housekeeping gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; see Table 1). Potential contam-
ination of mRNA samples by genomic deoxyribonucleic
acid (DNA) was checked by running reactions without
reverse transcriptase, using GAPDH primers for the sub-
sequent PCR amplification.
Real-time polymerase chain reaction (qPCR)
The expression of OSM, OSMR-β, gp130, GLAST, GLT-1,
and HIV LTR genes was analyzed by real-time PCR using
an iCycler (Bio-Rad, Veenendaal, The Netherlands) and iQ
SYBR Green supermix (Bio-Rad). The housekeeping gene,
hypoxanthine phosphoribosyl transferase 1 (HPRT1), was
used for normalization, and it showed no variations in
response to the experimental treatment (see Table 2 for
primer sequences). The comparative Ct method (amount
of target amplicon X in sample S, normalized to a refer-
ence R and related to a control sample C, calculated by 2
− ((CtX,S −CtR,S) − (CtX,C −CtR,C)) was used to deter-
mine the relative expression levels of all tested genes [46].
Linear regression analysis of the data was performed to
understand the effect of OSM treatment over time on the
expression of GLAST and GLT-1 mRNA.
Western blotting
Western blotting of primary astrocyte and microglia cell
lysates was performed as previously described [26]. Protein
calibration controls were performed to ensure that the
chosen working quantities were at non-saturating condi-
tions (Additional file 3: Figure S3B-C). Briefly, equal
amounts of protein (30 μg) were loaded onto 12.5 % so-
dium dodecyl sulfate-polyacrylamide gels and subsequently
transferred to PVDF membranes. The membranes were
blocked using Odyssey blocking buffer (OBB; diluted 1:1 in
PBS) for 1 h and incubated overnight at 4 °C with different
combinations of primary antibodies (diluted in 1:1 OBB
and PBS-T (PBS + 0.1 % Tween 20)): goat anti-OSMR-β,
rabbit anti-GLAST, rabbit anti-GLT-1, mouse anti-β-actin,
mouse anti-α-tubulin, mouse anti-STAT3, mouse anti-p44/
42 mitogen-activated protein kinase (MAPK), mouse anti-
Akt (Pan), rabbit anti-phospho STAT3 (Tyr705), rabbit
anti-phospho-p44/42 MAPK (Thr202/Tyr204), and rabbit
anti-phospho-Akt (Ser473). The next day, membranes were
washed in PBS-T (4 × 5 min) and incubated for 1 h at room
temperature (with gentle shaking in the dark) with appro-
priate fluorescent dye-conjugated secondary antibodies (di-
luted in PBS-T): donkey anti-goat IR Dye 800CW, donkey
anti-mouse IR Dye 680, and donkey anti-rabbit IR Dye
800CW. Membranes were washed again in PBS-T (4 ×
5 min), and fluorescent bands were detected using LI-
COR’s Odyssey infrared imaging system. The densitometry
analysis of protein bands was performed using ImageJ soft-
ware (NIH) [47].
OSM and IL-6 ELISA
Supernatants from cultured BV2, primary shake-off micro-
glia, and primary astrocytes were collected following Eco-
HIV infections, to measure secreted OSM levels using a
Table 1 Primers used for reverse transcription polymerase chain reaction (RT-PCR)
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mouse OSM ELISA-kit (USCN Life Science Inc., TX, USA)
following the manufacturer’s instructions. Secreted IL-6
levels in astrocyte culture supernatants were measured
using a mouse IL-6 ELISA Ready-SET-Go kit (Affymetrix,
eBioscience, CA, USA), following the manufacturer’s
instructions.
Determination of astrocytic glutamate uptake: 3H-D-
aspartate uptake assay
D-Aspartate was used as index of glutamate uptake in
this study as it is a substrate for the high-affinity glutam-
ate transporters with slow intracellular metabolization,
thus allowing a more precise measure of glutamate
transporter activity [48–50]. The analysis of 3H-D-aspar-
tate uptake was evaluated as previously described [41].
Briefly, cultured astrocytes were incubated with Krebs
buffer (in mM: 132 NaCl, 4 KCl, 1.2 Na2HPO4, 1.4
MgCl2, 6 glucose, 10 HEPES, 1 CaCl2, pH 7.4) contain-
ing 3H-D-aspartate (0.1 μCi/mL) and 50 μM D-aspartate
for 10 min at 37 °C. Subsequently, the medium was re-
moved and the cultured cells were placed on ice and
washed twice with cold NMG buffer (where NaCl is
replaced by N-methylglucamine, NMG) to terminate the
uptake process. The cells were lysed with 0.5 M NaOH
and transferred to a scintillation vial to be mixed with
liquid scintillation cocktail. The radioactivity content
(disintegrations per minute) was determined using liquid
scintillation counting on a TRICARB® 2900TR analyzer.
The remaining cell suspension was used to determine the
protein content with the bicinchoninic acid (BCA) method
(Pierce Technology) [51]. The uptake rate was expressed as
the uptake per minute per milligram of protein. For satur-
ation kinetics assays, the total D-aspartate concentrations
ranged from 5 to 200 μM. The kinetic constants (i.e.,
maximum velocity, Vmax, and Michaelis-Menten constant,
KM) were determined by using nonlinear regression fit of
the data with a rectangular hyperbola, using the GraphPad
Prism software (version 5.02, GraphPad Software Inc, La
Jolla, CA, USA).
Induction of excitotoxicity
Confluent astrocyte cultures were treated without or with
OSM (10 ng/mL for 24 h) in the presence or absence of
STAT3 activation inhibitor AG490 (25 μM, added 2 h be-
fore OSM). The cultures were then washed with warm
HBSS and incubated with glutamate (100 μM, diluted in
neuronal culture media) at 37 °C for 30 min. The superna-
tants from astrocytes incubated with glutamate, hereinafter
referred to as glutamateinc., were collected and applied (di-
luted 1:1 with neuronal media) onto 5 days old embryonic
cortical neuron cultures and incubated for 1 h at 37 °C.
Some neuron cultures were also treated with 50 μM glu-
tamate for 1 h (positive control for excitotoxicity). Where
indicated, neurons were pre-incubated with the NMDA
receptor antagonist, dizocilpine (MK 801; 30 μM) for
30 min before the glutamate or the glutamateinc. treatment.
Following glutamate treatment, the neuronal medium was
refreshed and cultures were incubated for the indicated
period of time before they were assessed for cellular dys-
function and cytotoxicity using MTT assay and propidium
iodide labeling, respectively.
Determination of neuronal viability
(1) MTT assay: The metabolic viability of cultured
embryonic cortical neurons was measured 24 h after
glutamate treatment by the colorimetric MTT (3-(4,5-
dimethylthiazol-2-yl-) 2,5-diphenyltetrazolium
Table 2 Primers used for real-time polymerase chain reaction (qPCR)
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bromide) assay, as described previously [26, 52]. MTT
solution (0.5 mg/mL final concentration) was added to
cultured neurons and incubated for 4 h. Following
incubation, the cells were lysed and MTT-formazan
solubilized in dimethyl sulfoxide (DMSO) with an
orbital shaker for 15 min. The optical density of each
sample was determined using an automated ELISA
reader (Varioskan Flash spectral scanning multimode
reader; Thermo scientific, USA) at 570 nm, with a
background correction at 630 nm.
(2)Propidium iodide labeling: Survival of cultured
cortical neurons was estimated using propidium
iodide (PI; DNA intercalating dye) labeling gauged
by immunocytochemistry, as described previously [26].
Briefly, neuronal cultures treated without or with
glutamate (or glutamateinc.) were incubated with PI
(5 μg/mL; directly added to culture media) for 4 h and
fixed in 4 % paraformaldehyde. After a few washes
with PBS, cells were blocked using 5 % normal goat
serum (NGS) diluted in PBS+ (PBS containing 0.1 %
Triton-X100) for 1 h at room temperature on a shaker
and subsequently stained with a mouse anti-MAP2
primary antibody (1:600; diluted in PBS+ with 1 %
NGS) and incubated overnight at 4 °C on a shaker.
Following primary antibody incubation, cells were
washed with PBS (4 × 5 min) and incubated with the
donkey anti-mouse secondary Alexa Fluor 488-
conjugated antibody (1:400; diluted in PBS+) for 1 h
at room temperature in the dark on an orbital shaker.
A counterstain with Hoechst 33342 (1:1000; diluted in
PBS) was performed to detect cell nuclei (not shown),
and fluorescent signals were analyzed by confocal
imaging using a Leica SP2 AOBS system (Leica
Microsystems, Heidelberg, Germany).
Statistical data analysis
The absolute data values were normalized to control in
order to allow multiple comparisons. Statistical analyses
were performed by one-way analysis of variance (ANOVA)
followed by Bonferroni and Dunnett post hoc tests, using
the Statistical Package for the Social Sciences (SPSS,
Chicago, IL, USA) and GraphPad Prism software (ver-
sion 5.02, GraphPad Software Inc, La Jolla, CA, USA).
In all cases, p values <0.05 were considered statistically
significant.
Results
OSM down-regulates GLT-1 and GLAST expression in primary
mouse cortical astrocytes
Existing literature demonstrates that, in mice, OSM acts
on target cells through a receptor complex consisting of a
ligand recognition subunit (OSMR-β) and a signal trans-
ducing subunit (gp130) [53, 54]. Furthermore, all receptor
components required for OSM signaling are expressed in
human astrocytes [36]. In the present work, we first
confirmed expression of gp130 and OSMR-β mRNA in
cultured cortical astrocytes established from neonatal (P2)
mouse brains (Fig. 1a). We next investigated whether acti-
vation of OSM receptors in cortical astrocytes regulates
expression of GLT-1 and GLAST genes in vitro. Cultured
astrocytes treated with recombinant mouse OSM (10 ng/
mL) for different time periods (2, 4, 8, 12, and 24 h) were
analyzed for GLT-1 and GLAST mRNA expression by
real-time PCR (Fig. 1b). Linear regression analysis showed a
time-dependent reduction of the expression of GLT-1 (R2
= 0.415, p = 0.001, n = 3) and GLAST (R2 = 0.525, p < 0.001,
n = 3) mRNA in OSM-treated astrocytes compared to the
control; this effect was apparent after 4 and 8 h of OSM
incubation, for GLAST and GLT-1, respectively (Fig. 1b). In
order to understand whether the 5 % microglial cells
present in astrocyte cultures influence this effect of OSM,
we depleted microglial cells with liposomal clodronate
(1 mg/mL for 4 h) before addition of OSM (Additional file
2: Figure S2A-B). Treatment with OSM (10 ng/mL for
24 h) of microglia-depleted astrocyte cultures reduced both
GLT-1 and GLAST mRNA (p < 0.001, n = 3) (Additional
file 2: Figure S2B), and this effect of OSM was comparable
to the observations made from astrocyte cultures contain-
ing 5 % microglia (Fig. 1b) further establishing that OSM
receptors are primarily expressed in astrocytes.
It is well known that astrocyte cultures, due to the ab-
sence of soluble neuronal factors, express GLT-1 protein at
very low levels [55, 56]. Consistently, in our study, GLT-1
protein levels in cultured cortical astrocytes were minimally
detected by Western blot (Additional file 3: Figure S3C-D)
and thus making them difficult to quantify. In contrast,
GLAST proteins were robustly expressed in astrocyte cul-
tures (Additional file 3: Figure S3B). Treatment with OSM
(10 ng/mL) induced a time-dependent reduction of GLAST
protein density (Fig. 1c), consistent with the reduction
of GLAST mRNA levels (Fig. 1b). When compared to
the untreated control, a 5-h OSM treatment significantly
decreased of GLAST protein density (30.0 ± 7.0 %, n = 3,
p < 0.01), while a 24-h OSM treatment further decreased
GLAST protein density (60.1 ± 2.4 %, n = 3, p < 0.001)
(Fig. 1c).
OSM inhibits 3H-D-aspartate uptake in primary mouse
cortical astrocytes
We next investigated whether the down-regulation of GLT-
1 (mRNA) and GLAST (mRNA and protein) by OSM had
consequences on the ability of astrocytes to clear extracellu-
lar glutamate. The rate of 3H-D-aspartate uptake, as deter-
mined by the saturation isotherm, was maximal when
astrocytes were incubated with 50 μM of 3H-D-aspartate
for 10 min at room temperature (Fig. 2a). As shown in
Fig. 2b, cultured astrocytes treated with OSM (1 or 10 ng/
mL, for 24 h) displayed a concentration-dependent
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decrease of 3H-D-aspartate uptake (OSM 1 ng/mL: 12.2 ±
2.2 % decrease, n = 3, p < 0.05; OSM 10 ng/mL: 24 ± 4 %
decrease, n = 3, p < 0.01).
JAK/STAT3 inhibition prevents OSM-induced reduction of
astrocytic 3H-D-aspartate uptake
It has been previously shown that OSM binding to the
OSMR-β/gp130 receptor complex results in phosphoryl-
ation of tyrosine residues of the gp130 receptor; this
triggers the recruitment, phosphorylation, and activation of
STAT proteins, mainly STAT1, STAT3, and STAT5 [57–
59]. In addition, OSM activates other signaling pathways
such as phosphatidylinositol 3-kinase (PI3K/Akt) [60] and
the MAPK, namely, ERK1/2, p38, and c-jun N-terminal
kinases/stress-activated protein kinases (JNK/SAPK) [61].
We next investigated whether treatment with OSM in-
duced phosphorylation of the three principal downstream
pathways: JAK/STAT3, PI3K/Akt, and ERK1/2-MAPK [35]
in cultured astrocytes. As shown in Fig. 3a, basal activation
of ERK1/2 and Akt proteins, but not STAT3, was observed
in untreated (control) primary astrocytes. OSM treatment
(10 ng/mL for 1 h) induced the phosphorylation at Tyr705,
Ser473, and Thr202/Tyr204 residues of STAT3, Akt, and
ERK1/2 proteins, respectively (Fig. 3a). Treatment of cul-
tured astrocytes (2 h prior to OSM) with selective inhibitors
of PI3K (LY294002, 25 μM), MEK1/2 (U0126, 5 μM), and
Fig. 1 OSM down-regulates GLT-1 and GLAST expression in primary mouse cortical astrocytes. a Total mRNA purified from wild-type (C57BL/6J) mouse
neonatal (P2) brain cortex as well as from cultured cortical astrocytes established from P2 brains was analyzed for expression of OSMR-β and gp130 mRNA
by reverse transcriptase PCR; GAPDH primers were used as loading control. b Cortical astrocyte cultures were treated without or with OSM (10 ng/mL) for
2, 4, 8, 12, and 24 h and analyzed for GLT-1 and GLAST mRNA levels (gene expression normalized to HPRT1) by real-time PCR. Data are normalized to
untreated controls and presented as mean ± SEM; n= 3, **p< 0.01, ***p< 0.001; one-way ANOVA using Bonferroni correction. c Cortical astrocytic cultures
were treated without or with OSM (10 ng/mL) for 3, 5, and 24 h and were analyzed for GLAST proteins by Western blot. Relative densitometric analysis of
GLAST proteins is shown in the lower panel. Data are presented as percentage of each respective ratio between optical density value of GLAST band
intensity and optical density value of the matched α-tubulin (which served as the loading control) band intensity; n= 3, **p< 0.01, ***p< 0.001;
one-way ANOVA
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JAK (AG490, 25 μM) inhibited OSM-induced phosphoryl-
ation of Akt, ERK1/2, and STAT3 proteins, respectively
(Fig. 3a). In the subsequent experiments, we investigated
how selective inhibition of PI3K/Akt, ERK1/2, and JAK/
STAT3 signaling pathways regulated OSM-induced reduc-
tion of glutamate transporter activity in cultured astrocytes.
Treatment with OSM or AG490 did not affect the survival
of cultured astrocytes (Fig. 3b), whereas both LY294002
and U0126 induced about 20 % reduction (p < 0.01) in
astrocyte survival (Fig. 3b). The blockade of Akt, ERK1/2,
and STAT3 signaling pathways occluded the OSM-induced
inhibition of 3H-D-aspartate uptake (Fig. 3c). However,
whereas AG490 did not modify astrocytic 3H-D-aspartate
uptake, both LY294002 and U0126 decreased per se the up-
take of 3H-D-aspartate (Fig. 3c). Taken together, these
results indicate that STAT3 activation is sufficient to medi-
ate the ability of OSM to impair glutamate uptake in mouse
cortical astrocytes.
OSM-induced inhibition of astrocytic glutamate uptake
promotes NMDA-mediated excitotoxicity in cortical neurons
in vitro
We next tested if this ability of OSM to inhibit astrocytic
glutamate uptake translated into a detrimental effect of
OSM on neurons. In order to investigate this, cultured
astrocytes with or without OSM pre-treatment (10 ng/
mL for 24 h) were incubated with glutamate (100 μM
for 30 min). The glutamateinc. (see Methods) was then
applied to neuronal cultures. After 1 h of incubation at
37 °C, the medium was refreshed and neuronal viability
Fig. 2 OSM inhibits D-aspartate uptake in primary mouse cortical astrocytes. a Shows saturation isotherm of Na+-dependent 3H-D-aspartate
uptake by astrocytes. Primary astrocytes from wild-type (C57BL/6J) mouse neonatal (P2) brains were incubated with 3H-D-aspartate (0 to 200 μM)
dissolved either in a Na+ buffer or in a Na+-free buffer (where Na+ is replaced by N-methyl-D-glucamine chloride, NMG, to determine nonspecific
tritium retention) for 10 min at room temperature. Each point represents the mean ± SEM of at least three separate experiments, measured in triplicate.
Kinetic constants were determined by nonlinear regression fit or a rectangular hyperbola, where Vmax was 0.3 μM± 0.08 and KM was 22.4 μM (95 %
confidence interval: 0.17–0.34 μM). b Shows the effect of OSM treatment (1 and 10 ng/mL; for 24 h) on 3H-D-aspartate uptake in cortical astrocytes
culture. Data are normalized to untreated controls and presented as mean ± SEM; *p < 0.05, **p < 0.01, n = 3 to 17; one-way ANOVA followed by
Dunnett’s multiple comparison test
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was assessed after 4 and 24 h by immunocytochemistry
and MTTassay, respectively (Fig. 4a, b). As a positive con-
trol, we used a direct addition of glutamate (50 μM) to
neuronal cultures, which decreased neuronal viability by
approximately 45 % (Fig. 4a) [26]. This glutamate-induced
neuronal excitotoxicity was NMDA receptor-dependent
since MK 801 (NMDA receptor antagonist; 30 μM) abol-
ished the toxic effect of glutamate (F = 13.321; p < 0.001)
(Fig. 4a). Finally, we observed that glutamateinc. from
OSM-treated astrocytes, but not untreated astrocytes, also
reduced neuronal viability (OSM treated 67.1 ± 14.24 %
survival, n = 4, p < 0.001 and untreated 98.4 ± 5.4 % sur-
vival, n = 4), when compared to the untreated control
(Fig. 4a). These results were further confirmed by direct
measure of neurotoxicity using PI staining (Fig. 4b). By
contrast, neuronal viability was preserved when the cul-
tures were co-treated with MK-801 (Fig. 4a), confirming
that the neurotoxicity induced by glutamateinc. from
OSM-treated astrocytes was dependent on neuronal
NMDA receptor activation. Since OSM-induced inhib-
ition of glutamate uptake in cultured astrocytes was
reversed by the JAK/STAT3 signaling inhibitor, AG490
(Fig. 3c), glutamateinc. from cultured astrocytes that were
pre-treated simultaneously with OSM and AG490 should
not cause neuronal cell death. Indeed, neuronal viabil-
ity was unchanged by glutamateinc. from OSM-treated
astrocytes where JAK/STAT3 activation was blocked
(F = 13.321; p < 0.001) (Fig. 4a), reinforcing that OSM-
induced inhibition of astrocytic glutamate transporter ac-
tivity is regulated by the JAK/STAT3 signaling pathway.
Fig. 3 Inhibition of JAK/STAT3, but not PI3K/Akt or MEK/ERK1/2
signaling pathways, prevents OSM-induced reduction of 3H-D-aspartate
uptake in primary cortical astrocytes. a Shows the effect of 2 h pre-
treatment with selective inhibitors of PI3K (LY294002, 25 μM), MEK1/2
(U0126, 5 μM), and JAK (AG490, 25 μM) on activation of Akt, ERK1/2, or
STAT3 proteins, respectively, in OSM-treated (10 ng/mL for 1 h) astrocytes
culture. Activation of different signaling proteins was evaluated by
Western blot using antibodies that selectively detect the phosphorylation
at Ser473, Thr202/Tyr204, and Tyr705 residues of Akt, Erk1/2, and STAT3,
respectively. Total amounts of each protein were detected using
appropriate antibodies (see the “Methods” section); β-actin served as
loading control. b Shows the effect of OSM (10 ng/mL), LY294002
(25 μM), U0126 (5 μM), and AG490 (25 μM) treatments for 24 h on the
viability of cultured cortical astrocytes. Cell viability was measured using
a colorimetric MTT assay. OD measurements were made at 570 nm,
with a blank correction made at 630 nm. Data are presented as
percentage of untreated (control) astrocytes; each bar represents the
average of four independent experiments done in quadruplicates.
*p < 0.01. c Shows the effect of pre-treatment with LY294002 (25 μM),
U0126 (5 μM), and AG490 (25 μM) on 3H-D-aspartate uptake in
untreated and OSM-treated (10 ng/mL, for 24 h) astrocyte cultures.
Data are normalized to untreated controls and presented as
mean ± SEM; **p < 0.001 (compared to untreated control);
##p < 0.001 (compared to OSM); n = 8; one-way ANOVA
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Fig. 4 (See legend on next page.)
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EcoHIV induces the expression and release of OSM in
cultured BV2 cells and primary microglia
A recent study showed that PBMCs isolated from
neurologically compromised HIV-1-infected patients
spontaneously secreted high levels of OSM, whereas
OSM levels secreted from PBMCs of neurologically
asymptomatic HIV-1 patients were comparable to that
of age-matched healthy subjects [20]. Furthermore, this
OSM produced by PBMCs isolated from HIV-1-
infected individuals induces toxicity in cultured primary
human fetal neurons [29]. These findings strongly sug-
gest an important role for OSM in neuropathogenesis
and/or neurocognitive impairments observed in HIV-1-
infected patients. However, it is not known if HIV-1
infection induces OSM production in microglial cells, a
potential source for OSM in the CNS [18, 62]. In order
to address this question, we next investigated the
expression and release of OSM in cultured microglial
cells that were infected with EcoHIV. The viral infection
of BV2 cells for 4 h increased GFP-immunoreactivity
(Fig. 5a), indicating successful viral infection. The viral in-
fectivity of BV2 cells increased with time, as HIV LTR
gene expression following 24 h of EcoHIV incubation was
significantly higher when compared to that at 4 h of
viral incubation (approx. 103-fold increase at 4 h, p <
0.001; and 106-fold increase at 24 h, p < 0.0001, n = 6)
(Fig. 5b). Next, real-time PCR analysis of OSM gene in
EcoHIV-infected BV2 cells showed a fivefold increase
in expression of OSM mRNA both at 4 h (p < 0.05)
and 24 h (p < 0.01) of viral incubation, when compared
to uninfected controls (Fig. 5c). In addition, EcoHIV
induced OSM release from BV2 cells, since the super-
natants from infected cells (24 h following viral incu-
bation) contained higher levels of secreted OSM (n = 2
in triplicates, p < 0.01), compared to the uninfected
controls (Fig. 5d). We further confirmed the above
findings in primary mouse microglia, as the culture
supernatants contained elevated OSM levels (n = 6, p
< 0.05) following 24 h of EcoHIV infection (Fig. 6a, b).
EcoHIV induces gp130 mRNA, but not OSMR-β mRNA or
protein, in cultured primary microglia
We next analyzed whether EcoHIV infection regulates ex-
pression of OSM receptor subunits (gp130 and OSMR-β)
in cultured primary microglia. As shown in Fig. 6c, EcoHIV-
infected microglia (following 24 h of treatment) showed a
2.4-fold increase in gp130 mRNA (n= 3, p < 0.05), when
compared to the uninfected control. On the other hand,
OSMR-β mRNA expression in primary microglia was not
affected by EcoHIV infection (Fig. 6c). We further analyzed
OSMR-β protein expression in primary microglia by
Western blot. We observed that neither control nor
EcoHIV-infected microglia express detectable levels of
OSMR-β proteins (Fig. 6d). These observations are in
line with a recent study that showed OSMR-β proteins
are absent in microglial cells [63].
EcoHIV does not affect OSM release but induces OSMR-β
mRNA and protein expression in cultured cortical
astrocytes
Like microglia, astrocytes may also serve as a source for
OSM in the CNS [18], since OSM immunoreactivity was
detected in brains from MS patients in microglia, reactive
astrocytes, and infiltrating leukocytes [18]. We next investi-
gated whether EcoHIV induces OSM release from astro-
cytes. Cultured cortical astrocytes were infected for 24 h
with EcoHIV, as confirmed by the HIV LTR gene expres-
sion (Fig. 7a), and culture supernatants were analyzed for
secreted OSM levels. Control astrocytes secreted low levels
of OSM (approximately 40 pg/mL) (Fig. 7b). However, in
contrast to microglia, EcoHIV infection did not increase
OSM secretion from cultured astrocytes (Fig. 7b).
It has been shown that HIV-1 directly inhibits glutamate
transporter expression and glutamate uptake in human
fetal astrocytes, without induction of pro-inflammatory
mediators [64], and this effect was largely reproduced by
treatment with the HIV-1 envelope protein gp120 alone
[64]. The chimeric EcoHIV that we used in the present
study does not contain gp120, as it is replaced with gp80
(See figure on previous page.)
Fig. 4 OSM-induced inhibition of astrocytic glutamate uptake promotes NMDA-mediated excitotoxicity in cortical neurons in vitro. Primary
cortical astrocyte cultures from wild-type (C57BL/6J) mouse neonates (P2) were treated with OSM (10 ng/mL, for 24 h) in the absence or presence
of a JAK/STAT3 inhibitor (AG490, 25 μM; added 2 h prior to OSM). Following OSM treatment, the cultures were washed once using warm HBSS
and incubated with glutamate (100 μM, diluted in Neurobasal media) for 30 min. The resulting astrocyte supernatant, designated as glutamateinc. (see the
“Methods” section), was applied (diluted 1:1 ratio in neuronal culture media) to 6-day-old neuronal cultures obtained from embryonic (~E15) mouse cortex.
As a positive control, neuronal cultures were treated with 50 μM glutamate, in the absence or presence of the NMDA receptor antagonist MK-801 (30 μM,
added 30 min prior to glutamate treatment). Following glutamate treatment (for 1 h), new medium was added to the neuronal cultures and they were
incubated at 37 °C in a CO2 incubator. a 24 h after glutamate treatment, cell viability was measured using a colorimetric MTT assay. OD measurements
were made at 570 nm, with a blank correction made at 630 nm. Data are presented as percentage of untreated (control) neurons; each bar represents the
average of four independent experiments done in quadruplicates. **p< 0.001 (compared to glutamate); ##p< 0.001 (compared to glutamateinc. from
OSM-treated astrocytes); one-way ANOVA using Bonferroni correction. b 4 h after glutamate treatment, cells were fixed in 4 % paraformaldehyde, washed,
and co-stained anti-MAP2 antibody (in green, neuronal marker) and propidium iodide (in red, showing cell death); scale bar corresponds to 25 μm
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from murine leukemia virus [39, 40]. Thus, EcoHIV serve
as a good model to investigate gp120-independent effects
of HIV-1 in murine cells. We next investigated how Eco-
HIV infection regulated GLAST and GLT-1 genes in cul-
tured cortical astrocytes. Interestingly, cultured astrocytes
infected for 24 h with EcoHIV showed a 2.5-fold increase
in GLT-1 mRNA (n = 3, p < 0.05) (Fig. 7c). By contrast,
GLAST gene expression was unchanged in EcoHIV-
infected astrocytes, when compared to the untreated con-
trol (Fig. 7c). We next investigated whether EcoHIV-
infected astrocytes displayed an enhanced gene expression
of OSM receptor subunits, OSMR-β, and gp130. As shown
in Fig. 7d, EcoHIV infection did not affect the expression of
gp130 mRNA in cultured astrocytes. On the other hand,
EcoHIV-infected astrocytes showed a fivefold increase in
the expression of OSMR-β mRNA (n = 3, p < 0.01),
compared to the uninfected control (Fig. 7d). Enhanced
astrocytic expression of OSMR-β following EcoHIV in-
fection was also observed at the protein level (n = 3, p
< 0.05) (Fig. 7e). Taken together, our findings suggest
that HIV-1 may additionally inhibit astrocytic glutam-
ate uptake by a gp120-independent mechanism that
involves a combined alteration of GLT-1 expression and
the induction of OSMR-β expression and signaling in
astrocytes.
Discussion
This is the first report to show that treatment with
OSM, a member of the IL-6 cytokine family, reduces
glutamate uptake in cultured cortical astrocytes and
thereby promotes excitotoxic death of cortical neurons
in vitro. This effect of OSM is mediated by the down-
regulation of the two Na+-dependent glutamate trans-
porters, GLAST, and GLT-1. As shown in Fig. 1b, OSM
treatment (10 ng/mL) reduces the expression of GLAST
and GLT-1 mRNA in a time-dependent manner. The
down-regulation of GLAST by OSM was also confirmed
at the protein level; however, the low signals obtained
with the GLT-1 antibody in the Western blot analysis
precluded any reliable analysis of the impact of OSM on
GLT-1 protein levels in cultured astrocytes (Additional file
3: Figure S3C-D). Consistent with the down-regulation of
glutamate transporter expression, OSM inhibited 3H-D-as-
partate uptake by astrocytes in a concentration-dependent
Fig. 5 EcoHIV induces expression and release of OSM in cultured BV2 cells. a Shows GFP (in green, showing infected cells) and DAPI (in blue,
showing nuclei) staining of control and EcoHIV-infected (35,000 pg of p24, for 4 h) BV2 cells; scale bar corresponds to 25 μm. b, c Show real-time
PCR analyses of HIV LTR (b) and OSM (c) mRNA in control and EcoHIV-infected (35,000 pg of p24) BV2 cells. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001, ###p < 0.001, n = 6. d Shows ELISA analysis of OSM proteins in culture supernatants collected from control and EcoHIV-infected
(35,000 pg of p24) BV2 cells; **p < 0.01, n = 2 (in triplicates)
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manner (Fig. 2b), which mostly involved the recruitment of
the JAK/STAT3 pathway (Fig. 3c), rather than the PI3K or
ERK1/2 pathways. This is in agreement with the previously
reported ability of OSM to induce STAT3 phosphorylation
in astrocytes [65], which we now confirmed (Fig. 3a). We
further showed that down-regulation of glutamate trans-
port in astrocytes by OSM decreased survival of cultured
cortical neurons. As shown in Fig. 4a, glutamateinc. (see the
“Methods” section) from untreated astrocytes did not affect
the survival of cortical neurons, suggesting that extracellu-
lar glutamate is rapidly taken up by astrocytes. However,
glutamateinc. from OSM-treated astrocytes did cause excito-
toxicity in cultured cortical neurons (Fig. 4a, b). It has been
previously shown that gp130-mediated STAT3 activation
precedes reactive gliosis in mouse astrocytes [33], which
might lead to nitric oxide-induced inflammatory death of
neurons [66]. In our current in vitro study, conditioned
media from OSM-treated astrocyte cultures did not affect
neuronal survival (Fig. 4a), and OSM treatment did not in-
duce the production of nitric oxide in astrocyte cultures
(Additional file 4: Figure S4), thus excluding the possibility
of indirect oxidative stress-induced neuronal damage.
These observations are supported by a recent study, where
the authors showed that nitric oxide synthase is not in-
duced by OSM in primary astrocytes and microglia [63].
Importantly, glutamateinc. from OSM-treated astrocytes did
not affect survival of neurons in the absence of neuronal
NMDA receptor activity (Fig. 4a), suggesting that the in-
creased neurotoxicity results from the decreased glutamate
uptake in OSM-treated astrocytes.
The regulation of extracellular glutamate by astrocytes
is determined by the density and activity of both glutam-
ate transporters and glutamine synthetase, the enzyme
that converts glutamate to glutamine [49]. Whether or not
OSM treatment regulates glutamine synthetase expression
or activity has not been addressed in this study. On the
other hand, we showed that OSM treatment induces the
expression of GFAP, COX2, and OSMR-β, but not gp130,
in cultured astrocytes (Additional file 5: Figure S5A-C). In
line with our findings, OSM has been previously shown to
induce pro-inflammatory factors such as GFAP and
COX2, among others in astrocytes [30, 35]. In addition,
gp130-mediated STAT3 activation in striatal astrocytes
has been reported to be closely associated with neuronal
damage in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) model of neurodegeneration in vivo [33]. Further-
more, OSM/gp130-mediated STAT3 activation has been
shown to mediate methamphetamine-induced astrogliosis
[32]. Based on these findings, we provide direct evidence
that the activation of OSM receptor, triggering STAT3
signaling in astrocytes, impacts neuronal survival. Thus,
blockade of STAT3 signaling in astrocytes might be
Fig. 6 EcoHIV induces OSM release and gp130 mRNA, but not OSMR-β mRNA or protein, in cultured primary mouse microglia. a Shows real-time
PCR analysis of HIV LTR mRNA in control and EcoHIV-infected (35,000 pg of p24, for 24 h) primary microglia. ****p < 0.0001, n = 3. b Shows ELISA
analysis of secreted OSM proteins in culture supernatants collected from control and EcoHIV-infected primary microglia. *p < 0.05, n = 6. c Shows
real-time PCR analysis of gp130 and OSMR-β mRNA in control and EcoHIV-infected primary microglia. *p < 0.05, n = 3. d Shows Western blot
analysis for OSMR-β proteins in control and EcoHIV-infected primary microglial cell lysates obtained from three independent experiments. β-Actin
served as the loading control
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beneficial to prevent excitotoxic neuronal death in
models pertinent to many brain injuries with an inflam-
matory profile [33].
Astrocyte dysfunction resulting in deficient glutamate
uptake and metabolism has been reported to be a major
contributing factor to the excitotoxic death of neurons
in different CNS disease conditions, including HAND
[11, 12]. Thus, the identification of essential factors that
regulate astrocytic glutamate transporter expression
and activity might be beneficial in HAND treatment. It
has been reported that HIV-1 could directly inhibit
glutamate transporter expression and uptake in human
fetal astrocytes, without induction of pro-inflammatory
mediators such as TNF-α [64]. The authors of this
study showed that the envelope protein, gp120, alone
induced effects similar to these of HIV-1 [64]. In our
study, we describe a potential gp120-independent mech-
anism for HIV-induced down-regulation of astrocytic
glutamate transport using EcoHIV, a chimeric HIV-1 that
can infect mouse cells [39, 40]. EcoHIV itself did not
down-regulate GLAST expression in cultured mouse cor-
tical astrocytes (Fig. 7c), whereas it enhanced GLT-1
mRNA expression by 2.5-fold. Interestingly, we show that
EcoHIV infection induces a fivefold increase in OSMR-β
Fig. 7 EcoHIV neither induces OSM secretion, nor the expression of gp130 or GLAST mRNA, but stimulates the expression of GLT-1 and OSMR-β
in primary cortical astrocytes. a Shows real-time PCR analyses of HIV LTR mRNA in control and EcoHIV-infected (35,000 pg of p24, for 24 h) cortical
astrocyte cultures. ****p < 0.0001, n = 3. b Shows ELISA analysis of secreted OSM proteins in culture supernatants collected from control and
EcoHIV-infected primary astrocyte cultures. n = 6. c, d Shows real-time PCR analyses of GLAST and GLT-1 (c) and gp130 and OSMR-β (d) mRNA in
control and EcoHIV-infected cortical astrocyte cultures. *p < 0.05, **p < 0.01, n = 3. e Shows Western blot analyses for OSMR-β proteins in control
and EcoHIV-infected cortical astrocyte culture lysates. The left panel shows representative blot of three independent experiments. The right panel
shows densitometric analysis of OSMR-β proteins. Data are presented as percentage of each respective ratio between optical density value of
OSMR-β band (110 kDa) intensity and optical density value of the matched β-actin (42 kDa; loading control) band intensity. *p = 0.027, n = 3;
two-tailed Student’s t test
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mRNA and proteins in cultured astrocytes (Fig. 7d, e),
whereas OSMR-β proteins in cultured microglia were un-
detectable by Western blot, as described previously [63].
We also provide evidence that EcoHIV infection induces
OSM mRNA expression and protein release in BV2 cells
and primary microglia (Figs. 5 and 6), but not in cultured
astrocytes (Fig. 7b). In addition, it is noteworthy that the
secreted OSM levels in untreated microglial culture super-
natants were drastically higher, when compared to that of
astrocytic culture supernatants (approximately 2000 and
40 pg/mL, respectively) (Figs. 6b and 7b), suggesting that
microglial cells might be a better source for OSM release
in the CNS [18, 62]. Further analysis using astrocyte-
selective OSMR-β deficient animals or cell cultures would
provide better insight into the role of OSM in EcoHIV-
mediated neuropathogenesis and/or impaired astrocytic
glutamate uptake. Several other pro-inflammatory media-
tors have been shown to regulate GLAST and GLT-1 ex-
pression in astrocytes, including TNF-α and IL-1β [67].
Real-time PCR analysis of TNF-α, IL-1β, cyclooxygenase-
2 (COX-2), iNOS, and IL-6 genes in primary microglia
showed an induction of these genes following EcoHIV infec-
tion (Additional file 6: Figure S6), indicating the complexity
of the inflammatory processes that lead to impaired astro-
cytic glutamate uptake associated with EcoHIV infection.
Comparison of the findings reported in the present
study with previous reports suggests that OSM has a com-
plex profile of action in the control of neurodegeneration.
In fact, previous studies demonstrated anti-inflammatory
as well as neuroprotective properties of OSM, both in
vitro and in vivo. For example, OSM inhibits production
of pro-inflammatory mediators such as TNF-α, granulo-
cyte macrophage colony-stimulating factor (GM-CSF),
and IL-8 [24, 25] and has been shown to suppress inflam-
matory processes associated with the murine experimental
allergic encephalomyelitis model of MS [24]. In addition,
we have previously provided evidence for a neuroprotec-
tive effect of OSM against glutamate by up-regulating
neuromodulatory adenosine A1 receptors [26]. In another
study, direct activation of neuronal OSM receptors down-
regulated the NR2C subunit of NMDA receptors and
thereby prevented NMDA-induced toxicity [27]. More
recently, the complex role of OSM signaling was further
demonstrated by the reported neuroprotective activity of
OSM against ischemic stroke, which is dependent on
neuronal OSMR-β expression and activation, with de-
creased neuronal OSMR-β expression leading to worse
stroke outcomes [28]. Taken together these findings and
our present study, it may be concluded that the target cell
addressed by OSM largely determines the pro- and anti-
excitotoxic effects of this cytokine in the CNS.
In the mammalian brain, astrocytes are the predomin-
ant players in regulating the glutamate diffusion and spill
over from perisynaptic areas, a pre-requisite process to
maintain the high signal-to-noise ratio for synaptic com-
munication [6, 49]. Therefore, compromised astrocytic
glutamate uptake function caused by the overproduction
of cytokines such as OSM, concomitant or resulting
from brain injury, might synergistically exacerbate the
accumulation of extracellular glutamate at excitotoxic
concentrations leading to neuronal damage. In spite of
their various suggested roles in astrocytic metabolism,
IL-6 family members such as OSM have been scantily
explored in their effects on glutamate uptake. There is
evidence that CNTF, in contrast to our present findings
with OSM, enhances both expression and activity of
GLT-1 in astrocytes [68] and thereby promotes survival
of neurons against excitotoxicity [69]. Several reports
suggest an induction of IL-6 in astrocytes by variety of
HIV proteins such as Tat, gp120, Nef, and Vpr [70–73].
Consistently, we show here that infection with EcoHIV
virus for 24 h induces several-fold increase in IL-6 secre-
tion in primary astrocytes (Additional file 7: Figure S7).
However, IL-6 was shown to have no effect on glutamate
uptake on cultured murine astrocytes [74, 75], although
it suppressed the increased glutamate uptake induced by
prostaglandin E2 (PGE2) [74]. Our preliminary findings
show that IL-6 treatment (10 ng/mL for 24 h) did not
significantly reduce GLT-1 mRNA expression in cultured
astrocytes (p = 0.08, n = 5) (Additional file 8: Figure S8).
On the other hand, we observed approximately 20 % re-
duction of GLAST mRNA (p = 0.04, n = 5) in IL-6-
treated astrocyte culture (Additional file 8: Figure S8).
However, this effect of IL-6 is mild, compared to the
effect of OSM (10 ng/mL for 24 h) on GLAST gene
expression in astrocytes (Fig. 1b and Additional file 2:
Figure S2B), and requires further validation at the pro-
tein level. Taken together, in this study, we have shown
that OSM, through STAT3 activation, impairs the cap-
acity of astrocytes to remove glutamate from extracellu-
lar space, which may contribute to excitotoxic neuronal
damage. This indicates that a better understanding of
OSM signaling mechanisms regulating glutamate trans-
porter level and activity may have important implications
for developing novel strategies to limit excitotoxic brain
damage in acute and neurodegenerative pathologies.
Conclusions
OSM is a pleiotropic cytokine belonging to the IL-6 family
that may differentially affect neuroinflammatory processes
associated with disease conditions of the CNS. We have
previously shown that OSM protects cultured neurons
against glutamate-induced excitotoxicity, whereas others
have reported that OSM mediates HIV-1-associated neuro-
toxicity, although the underlying mechanisms are unclear.
Here, we provide the first evidence that OSM inhibits
glutamate uptake process in astrocytes and thereby medi-
ates neuronal excitotoxicity. We further demonstrate that a
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chimeric HIV-1 virus that infects murine cells (EcoHIV)
induces expression and release of OSM in microglia and its
receptor (OSMR-β) in astrocytes. Taken together, our
findings suggest that targeting OSMR-β signaling in
astrocytes might alleviate HIV-1-associated neuronal
excitotoxicity.
Additional files
Additional file 1: Figure S1. Representative image (on top) showing
the characteristic ratio of astrocytes-to-microglia in the cortical astrocytes
culture. The cells were fixed in 4 % paraformaldehyde, immunostained for
GFAP (astrocytes; in green) and CD11b (microglia; in red) and observed
under a fluorescence microscope with a total magnification of ×1000. The
graph below shows the average astrocyte cell number (~152) compared
with the average microglial cell number (~10) after counting 10 microscopic
fields in several 16 mm coverslips of astrocyte cultures in 4 independent
experiments. The astrocyte purity was determined to be between 94 and
96 %. Scale bar corresponds to 20 μm. (TIF 16116 kb)
Additional file 2: Figure S2. OSM down-regulates GLT-1 and GLAST
expression in microglia-depleted primary mouse cortical astrocytes. (A)
Representative image showing the purity of cultured astrocytes following
treatment with liposome clodronate (1 mg/mL for 4 h). The cells were washed
with PBS, fixed in 4 % paraformaldehyde, immunostained for GFAP (astrocytes;
in green) and CD11b (microglia; in red) and observed under a fluorescence
microscope with a total magnification of ×1000. Scale bar corresponds to
20 μm. (B) Shows real-time PCR analyses of GLT-1 and GLAST mRNA (gene
expression normalized to HPRT1) in control and OSM-treated (10 ng/mL for
24 h) astrocyte cultures. The cultures used in this experiment were treated
with liposomal clodronate for 4 h, washed three times with PBS, and
incubated in fresh culture media for 24 h, before addition of OSM. Data are
normalized to untreated controls and presented as mean ± SEM; **p< 0.01,
n= 3. (TIF 8798 kb)
Additional file 3: Figure S3. Primary mouse astrocyte cultures
differentially express GLAST and GLT-1 transporters. (A) Cortical astrocyte
cultures were established from wild-type (C57BL/6J) mouse neonatal (P2)
brains, and total RNA was isolated and analyzed for the expression of
GLAST (91 bp) and GLT-1 (86 bp) mRNA by reverse transcriptase PCR
(see Table 1 for primer details); GAPDH (not shown) served as the loading
control. (B, C) Protein lysates prepared from cultured astrocytes were
analyzed for GLAST (B) and GLT-1 (C) protein levels by Western blot.
α-Tubulin served as the loading control. The observation that GLT-1
proteins were only faintly detected when high amounts of protein were
loaded is consistent with the previously published findings that showed GLT-1
protein in astrocyte cultures is expressed at almost undetectable levels [55, 56].
(D) Shows Western blot analysis of GLT-1 proteins in lysates prepared from
adult mouse cortex (12-week-old), neonatal (P2) brain regions (hippocampus,
olfactory bulb, cerebellum and cortex), and cultured cortical astrocytes
obtained from P2 mouse brains. As shown, GLT-1 proteins were abundantly
expressed in the adult mouse cortex, whereas their expression level in
different brain regions of P2 mouse brain was very low. β-Actin served as
the loading control. (TIF 14907 kb)
Additional file 4: Figure S4. OSM treatment does not induce nitric
oxide (NO) release in cultured cortical astrocytes. Cortical astrocyte cultures
from wild-type (C57BL/6J) mouse neonatal (P2) brains were treated without
or with OSM (10 ng/mL) for 2, 4, 8, 12, and 24 h. Following OSM incubation,
the supernatants were directly analyzed for NO content using Griess reagent
system as per manufacturer’s protocol. Data represent absolute values of
NO concentration and are mean ± SEM of two independent experiments
performed in triplicates. (TIF 6742 kb)
Additional file 5: Figure S5. OSM treatment induces GFAP, OSMR-β,
and COX-2 gene expression in cultured cortical astrocytes. (A) Shows
real-time PCR analysis of GFAP mRNA in primary astrocyte cultures that
were treated without or with OSM (10 ng/mL) for 2, 4, 8, 12, and 24 h.
GFAP gene expression was transiently induced by OSM, peaking at 8–
12 h of treatment. *p < 0.05, n = 3. (B) Shows enhanced GFAP (green)
immunoreactivity in cultured astrocytes following 8 h of OSM treatment
(10 ng/mL), compared
to the untreated control. Scale bar corresponds to 20 μm. (C) Shows
real-time PCR analysis of OSMR-β, gp130, and COX-2 mRNA in primary
astrocyte cultures that were treated without or with OSM (10 ng/mL) for
24 h. As shown, OSM induced two- and fivefold increase in OSMR-β and
COX-2 mRNA, respectively. *p < 0.05, **p < 0.01, n = 3. (TIF 19046 kb)
Additional file 6: Figure S6. EcoHIV infection induces the expression
of pro-inflammatory genes in primary microglia. Real-time PCR analysis
of TNF-α (A), IL-1β (B), COX-2 (C), iNOS (D), and IL-6 (E) mRNA were performed
in cultured primary microglia that were infected without (control) or with
EcoHIV (35,000 pg of p24, for 24 h). As shown, infection with EcoHIV induced
approximately 5-, 45-, 11-, 350-, and 360-fold increase in TNF-α, IL-1β, COX-2,
iNOS, and IL-6 mRNA, respectively. *p< 0.05, **p < 0.01, ***p< 0.001,
****p< 0.0001, n= 3. (TIF 23465 kb)
Additional file 7: Figure S7. EcoHIV induces IL-6 release in cultured
primary mouse astrocytes. Secreted IL-6 proteins in culture supernatants
from control and EcoHIV-infected (35,000 pg of p24, for 24 h) primary
astrocytes were measured using a mouse IL-6 ELISA Ready-SET-Go kit
(Affymetrix, eBioscience), following the manufacturer’s instructions.
****p < 0.0001, n = 6. (TIF 4562 kb)
Additional file 8: Figure S8. IL-6 down-regulates GLAST, but not GLT-1,
mRNA in primary mouse cortical astrocytes. Graph shows real-time PCR
analyses of GLT-1 and GLAST mRNA (gene expression normalized to HPRT1)
in control and IL-6-treated (10 ng/mL for 24 h) astrocyte cultures. Data are
normalized to untreated controls and presented as mean ± SEM. *p= 0.04
(GLAST); p= 0.08 (GLT-1); n= 5; two-tailed Student’s t test. (TIF 6507 kb)
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